{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:08:07Z","timestamp":1794632887629,"version":"4.9.1"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to evaluate the performance of cardiovascular (CV) risk prediction tools in identifying patients with systemic lupus erythematosus (SLE) with coronary artery calcification (CAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a post hoc analysis of a prior case-control study of adult female patients with SLE and matched controls. We excluded patients who already met cardiology guidelines for recommended statin use. We risk-stratified patients per Atherosclerotic CV Disease (ASCVD) Risk Score and SLE-specific CV Risk (SLECRISK) score and determined rates of abnormal CAC. We used 2-sample\n                      <jats:italic>t<\/jats:italic>\n                      tests, 2-sample Wilcoxon rank-sum (Mann-Whitney) tests, and chi-square tests to compare various characteristics between subgroups, and used logistic regression to assess adjusted risk for patients with SLE compared to controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 128 patients with SLE and 138 controls. Rates of abnormal CAC in the SLE and control groups were 31.3% (40\/128) and 12.3% (17\/138), respectively, with similar mean ASCVD Risk Scores (2.2% vs 1.9%). Both the ASCVD Risk Score and SLECRISK score had relatively high specificity (95-100%) for abnormal CAC. The ASCVD score demonstrated poor sensitivity in both control (17.6%) and SLE (15%) groups, with sensitivity doubling to 30.8% among patients with SLE with the use of the SLECRISK score. Among participants with SLE who had low ASCVD risk, those with abnormal CAC were more likely to be older and have lower glomerular filtration rate, longer disease duration, higher insulin resistance, and higher low-density lipoprotein and cholesterol levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The poor performance of conventional and even modified risk scores suggests a continued need for screening approaches, including CAC, to determine CV disease risk in the SLE patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0465","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T13:20:12Z","timestamp":1763212812000},"page":"637-644","source":"Crossref","is-referenced-by-count":4,"title":["Performance of Risk Score Calculators in the Identification of Coronary Artery Calcification in Patients With Systemic Lupus Erythematosus"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2256-9586","authenticated-orcid":false,"given":"Heta","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Von Feldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0799-7563","authenticated-orcid":false,"given":"Joshua F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"2026061213100667000_53.6.637.1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/keab362","article-title":"All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study","volume":"61","author":"Moghaddam","year":"2021","journal-title":"Rheumatology"},{"key":"2026061213100667000_53.6.637.2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000454"},{"key":"2026061213100667000_53.6.637.3","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.98"},{"key":"2026061213100667000_53.6.637.4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001247"},{"key":"2026061213100667000_53.6.637.5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122"},{"key":"2026061213100667000_53.6.637.6","first-page":"709","article-title":"The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study","volume":"56","author":"Hermansen","year":"2017","journal-title":"Rheumatology"},{"key":"2026061213100667000_53.6.637.7","doi-asserted-by":"crossref","first-page":"107466","DOI":"10.1016\/j.intimp.2021.107466","article-title":"Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis","volume":"94","author":"Lu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026061213100667000_53.6.637.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I"},{"key":"2026061213100667000_53.6.637.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00922-y"},{"key":"2026061213100667000_53.6.637.10","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-014-0435-z"},{"key":"2026061213100667000_53.6.637.11","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000528"},{"key":"2026061213100667000_53.6.637.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.05.008"},{"key":"2026061213100667000_53.6.637.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471"},{"key":"2026061213100667000_53.6.637.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21967"},{"key":"2026061213100667000_53.6.637.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.846"},{"key":"2026061213100667000_53.6.637.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg436"},{"key":"2026061213100667000_53.6.637.17","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000564"},{"key":"2026061213100667000_53.6.637.18","doi-asserted-by":"crossref","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026061213100667000_53.6.637.19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/eurjpc\/zwaa256","article-title":"Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus","volume":"28","author":"Drosos","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026061213100667000_53.6.637.20","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071870"},{"key":"2026061213100667000_53.6.637.21","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000409"},{"key":"2026061213100667000_53.6.637.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090312"},{"key":"2026061213100667000_53.6.637.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2026061213100667000_53.6.637.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx566"},{"key":"2026061213100667000_53.6.637.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2525"},{"key":"2026061213100667000_53.6.637.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0341-6"},{"key":"2026061213100667000_53.6.637.27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.14423\/SMJ.0000000000000561","article-title":"Effects of statin therapy in patients with systemic lupus erythematosus","volume":"109","author":"Artola","year":"2016","journal-title":"South Med J"},{"key":"2026061213100667000_53.6.637.28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study","volume":"243","author":"Yu","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026061213100667000_53.6.637.29","doi-asserted-by":"publisher","DOI":"10.1186\/ar3402"},{"key":"2026061213100667000_53.6.637.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"2026061213100667000_53.6.637.31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10067-017-3860-x","article-title":"Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology\/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis","volume":"37","author":"Jafri","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026061213100667000_53.6.637.32","doi-asserted-by":"crossref","unstructured":"Quevedo-Abeledo JC , Gonz\u00e1lez-Gay M\u00c1 , Ferraz-Amaro I. SCORE2 versus SCORE in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2022;14:1759720X221092373.","DOI":"10.1177\/1759720X221092373"},{"key":"2026061213100667000_53.6.637.33","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000272"},{"key":"2026061213100667000_53.6.637.34","doi-asserted-by":"crossref","first-page":"e019589","DOI":"10.1161\/JAHA.120.019589","article-title":"Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC\/AHA multisociety cholesterol treatment guidelines over the pooled cohort equation: insights from 3 large prospective cohorts","volume":"10","author":"Akintoye","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026061213100667000_53.6.637.35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10067-019-04856-z","article-title":"Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies","volume":"39","author":"Masson","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026061213100667000_53.6.637.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150983"},{"key":"2026061213100667000_53.6.637.37","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001152"},{"key":"2026061213100667000_53.6.637.38","first-page":"52","article-title":"Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus","volume":"80","author":"Serikova","year":"2008","journal-title":"Ter Arkh"},{"key":"2026061213100667000_53.6.637.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker307"},{"key":"2026061213100667000_53.6.637.40","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000014483.43921.8C"},{"key":"2026061213100667000_53.6.637.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392703"},{"key":"2026061213100667000_53.6.637.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00872-X"},{"key":"2026061213100667000_53.6.637.43","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00460-2"},{"key":"2026061213100667000_53.6.637.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.2.210"},{"key":"2026061213100667000_53.6.637.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.051"},{"key":"2026061213100667000_53.6.637.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"2026061213100667000_53.6.637.47","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-008-9319-z"},{"key":"2026061213100667000_53.6.637.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.06.018"},{"key":"2026061213100667000_53.6.637.49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/ITT.S377076","article-title":"Managing cardiovascular risk in systemic lupus erythematosus: considerations for the clinician","volume":"12","author":"Semalulu","year":"2023","journal-title":"ImmunoTargets Ther"},{"key":"2026061213100667000_53.6.637.50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221733"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:11:08Z","timestamp":1781295068000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.3899\/jrheum.2025-0465"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0465","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}